Thanks to a technology transfer to a prominent Latin American science institution, Brazil is now able to manufacture the AstraZeneca Covid-19 vaccine domestically. In October 2020, the company reached an agreement with Canada to supply up to 76 million doses of its vaccine, and Medicago also received $173 million in funding support from the Government of Canada for its vaccine R&D.īrazil to manufacture AstraZeneca’s Vaxzevria at home The vaccine showed 71% efficacy in a late-stage trial against all variants of SARS-CoV-2 among more than 24,000 adults in Canada, the US, UK, Mexico, Argentina and Brazil. Quebec-based Medicago and GlaxoSmithKline said Thursday that Health Canada approved its plant-based Covid-19 vaccine. GSK/Medicago’s plant-based Covid-19 vaccine shows 71% efficacy in Mexico, Argentina and Brazil trials “Now, health advocates will work together to take down Pfizer’s patent wall brick by brick to ensure that everyone, everywhere has access to COVID treatments.” “Many countries, including most of Latin America, may endure supply shortages and unaffordable prices,” Public Citizen said in the letter. Director Burcu Kilic said, in a call with Endpoints News Friday, that the agreement was largely a public relations move by the Big Pharma. But Public Citizen said the deal left out much of the world. The Medicines Patent Pool and Pfizer struck an agreement to qualify generic manufacturers in 95 countries, many of which are classified as low- or lower-middle-income, to produce generic versions of Pfizer’s Covid-19 antiviral. The consumer advocacy nonprofit issued a statement Friday claiming the Big Pharma is building a patent wall by filing or intending to file patent applications in 61 countries, as well as four regional patent offices, for nirmatrelvir, a key component in Pfizer’s Covid-19 treatment Paxlovid. Public Citizen accuses Pfizer of building ‘patent wall’ for Covid treatment warns that “most of Latin America, may endure supply shortages and unaffordable prices” The company will look to add up to 100 people to its team as well. That list includes Brazil, Mexico, Colombia and Argentina. In a move to advance the commercialization of Moderna’s Covid-19 shot in Latin America, the biotech has inked a deal with a pharma native to the continent to help make and distribute its shot.Īdium Pharma will commercialize Spikevax across 18 countries in Latin America. Moderna partners with Latin American Pharma The team excels at complex cross-border transactions involving Bermuda, British Virgin Islands, Cayman Islands, Cyprus and Luxembourg vehicles.The latest from Latin American pharma, including Moderna’s push to build a regional presence and partnership network Pfizer’s health equity challenges in the region and Brazil’s local manufacturing of AstraZeneca’s vaccine and approval of three new cannabis-based products. The team of corporate and finance lawyers at Harneys have strong networks with industry players and service providers in key markets around the world and understand the business environment in which their clients operate. The Adium group operates one of the leading pharmaceutical businesses in Latin America, with presence in 17 countries across the region and a track record of over 40 years, dedicated to the manufacturing, packaging, distribution, and commercialization of pharmaceutical products. Mitrani, Caballero & Ruiz Moreno acted as instructing law firm. The Harneys team was led by Partner Josh Mangeot, with support from Associate Ed Lacey. by a consortium of lenders, including Banco Itaú Uruguay S.A., which also acted as sole lead arranger and book runner. in relation to the US$130 million term loan financing of its subsidiary Adium Pharma S.A. Harneys acted as BVI counsel to Adium Ltd.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |